Relapsed Ovarian Cancers Patients
Conditions
Brief summary
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.
Interventions
DRUGOlaparib
Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
Sponsors
AstraZeneca
ARCAGY/ GINECO GROUP
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Inclusion criteria
* Patients must be female ≥18 years of age * Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy * Patients can be either alive or deceased at the time of medical record abstraction * Patients should not have any objection that anonymized data will be collected and subjected to automated processing.
Exclusion criteria
* Patient that were given olaparib within a clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival (PFS) | through study completion, an average of 1 year | PFS (days) = date of progression - date of treatment start + 1 |
| overall Survival (OS) | through study completion, an average of 1 year | OS (days) = date of death - date of treatment start + 1 |
| incidence of events of clinical interest | through study completion, an average of 1 year | the following events: anemia, thrombopenia, nausea and vomiting, fatigue, myelodysplastic syndrome, upper respiratory infections, diarrhea, decreased appetite, dysgeusia and headache will be formally retrieved from the source documents. |
Countries
France
Outcome results
None listed